Program
Simvastatin
Also written as “simvastatin”, “ezetimibe (+) simvastatin” and “Fenofibrate/Simvastatin”.
Its studies are mostly in Hypercholesterolemia · Diabetes Mellitus, Type 2 · Hyperlipidemias · Cardiovascular Diseases · Hypertension, led by 11 companies.
Drug pageSimvastatin: every studyMany companies study it; this page follows only the 65 they lead. All 370 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organonits history only | 290 open or running | phase 4since Sep 7, 2005 | Sep 21, 2004 | none ahead |
| Abbottits history only | 80 open or running | phase 3since Mar 25, 2004 | Mar 25, 2004 | none ahead |
| Eli Lilly | 60 open or running | phase 2since Apr 15, 2010 | Apr 15, 2010 | none ahead |
| GlaxoSmithKlineits history only | 60 open or running | phase 3since Oct 28, 2005 | Oct 28, 2005 | none ahead |
| Merckits history only | 60 open or running | phase 3since May 24, 2007 | May 24, 2007 | none ahead |
| Pfizerits history only | 40 open or running | phase 4since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jul 21, 2010 | Jul 21, 2010 | none ahead |
| Biogenits history only | 10 open or running | phase 4since Jun 25, 2007 | Jun 25, 2007 | none ahead |
| Entero Therapeuticsits history only | 10 open or running | early phase 1since Oct 3, 2016 | Oct 3, 2016 | none ahead |
| Medtronicits history only | 10 open or running | early phase 1since Jul 21, 2008 | Jul 21, 2008 | none ahead |
| Viatrisits history only | 10 open or running | phase 4since Aug 30, 2005 | Aug 30, 2005 | none ahead |
Also a collaborator on its studies: Immunogenics, Regeneron Pharmaceuticals, Celerion and Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 15, 2010First study: phase 2 study in DyslipidemiasFirst studyNCT01105975 · 398 enrolled · United States, Denmark, Germany and more
- Oct 8, 2013Phase 1 study in Healthy VolunteersNCT01960140 · 40 enrolled · United Kingdom
- May 28, 2014Phase 1 study in Healthy VolunteersNCT02156492 · 62 enrolled · China
- Nov 20, 2014Phase 1 study in Healthy VolunteersNCT02300259 · 48 enrolled · United States
- Mar 16, 2016Phase 1 study in DyslipidemiasNCT02714569 · 60 enrolled · United States
- Dec 16, 2023Phase 1 study in ObesityNCT06186622 · 50 enrolled · United States
TargetBeta
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Atorvastatinrule | Viatris | phase 4 | 186 |
| rosuvastatinrule | AstraZeneca | phase 4 | 184 |
| pitavastatinrule | Kowa | phase 4 | 36 |
Studies
All 6 Eli Lilly leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06186622Obesity · United States | 1 | Completed | Jul 10, 2024 | 50 |
| NCT02714569Dyslipidemias · United States | 1 | Completed | Feb 15, 2017 | 60 |
| NCT02300259Healthy Volunteers · United States | 1 | Completed | Apr 2015 | 48 |
| NCT02156492Healthy Volunteers · China | 1 | Completed | Dec 2014 | 62 |
| NCT01960140Healthy Volunteers · United Kingdom | 1 | Completed | Dec 2013 | 40 |
| NCT01105975Dyslipidemias · United States, Denmark, Germany and more | 2 | Completed | Jun 2011 | 398 |
How it is read
Names in the registry
- “Simvastatin”, 44 entries
- “simvastatin”, 14 entries
- “ezetimibe (+) simvastatin”, 9 entries
- “Fenofibrate/Simvastatin”, 5 entries
- “Ezetimibe + Simvastatin”, 4 entries
Codes read as this program: MK0733.
Conditions, from the studies’ own filings
- Hypercholesterolemia, 35 studies
- Diabetes Mellitus, Type 2, 9 studies
- Hyperlipidemias, 7 studies
- Cardiovascular Diseases, 3 studies
- Hypertension, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.